Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 153 publications
Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.
Journal: Expert review of hematology
Published: June 10, 2026
Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.
Journal: Expert review of hematology
Published: June 10, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
Journal: Blood advances
Published: April 21, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.
Journal: Blood advances
Published: April 21, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.
Journal: American journal of hematology
Published: February 20, 2026
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.
Journal: Oncology and therapy
Published: February 13, 2026
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.
Journal: Blood
Published: December 15, 2025
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: December 09, 2025
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Journal: Blood cancer journal
Published: December 04, 2025
Second primary malignancy in multiple myeloma: does a prior malignancy matter?
Journal: Haematologica
Published: November 30, 2025
Last Updated: 09/26/2026